Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

767P - Phase I/II study of toripalimab with cisplatin-based concurrent IMRT for local advanced cervical cancer

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Cervical Cancer

Presenters

Ping Jiang

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

P. Jiang1, S. Wei2, C. Li2, A. Qu1, R. Liu3, M. Wang4, H. Guo5, J. Wang2

Author affiliations

  • 1 Department Of Radiation Oncology, Peking University Third Hospital, 100191 - Beijing/CN
  • 2 Radiation Oncology Department, Peking University Third Hospital, 100191 - Beijing/CN
  • 3 Rheumatology Immunology Department, Peking University Third Hospital, 100191 - Beijing/CN
  • 4 Medical Oncology Department, Peking University Third Hospital, 100191 - Beijing/CN
  • 5 Obstetrics And Gynecology Department, Peking University Third Hospital, 100191 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 767P

Background

Cisplatin-based concurrent chemoradiation therapy (CCRT) has been increasingly used for local advanced cervical cancer (LACC). However, recurrence is common after cisplatin-based CCRT. Several treatment strategies have been explored to further improve the outcome. We aimed to evaluate the safety and efficacy of anti-PD-1 (Toripalimab, a humanized immunoglobulin G monoclonal antibody against programmed death 1) combined with cisplatin-based concurrent IMRT for locally advanced cervical cancer.

Methods

This is an open-label, nonrandomized, prospective phase Ⅰ/II study in a single arm. Patients with untreated LACC (2018 FIGO stage IB3, IIA –IVA) were enrolled. All patients were treated with CCRT for 56 days including cisplatin (40 mg/m2, Q1W) combined with image-guidance volume modulated Arc therapy (IG-VMAT) to pelvis (50.4Gy in 28 fractions, pelvic and paraortic nodes with simultaneous nodal boost to 59.4 Gy, 28 fractions), and followed by HDR intracavitary (30-36 Gy in 5-6 fractions) brachytherapy. Toripalimab was administered intravenously at 240 mg every 2 week for 4 cycles. The primary endpoint was incidence and severity of acute adverse events up to 3 months of completing treatment. The secondary endpoints were ORR and PFS.

Results

From Sep 2020 to Sep 2022, a total of 30 patients were enrolled. Median age was 58 years [range: 23–71]. The median follow-up duration was 8.5 months [range: 3.2–27.3]. 29 patients (29/30, 96.7%) completed the treatment, 1 patient (1/30, 3.3%) terminated the treatment because of hemophagic syndrome, who with a history of liver fluke disease. ORR was 100.0% (30/30) at 3 months after treatment. Treatment-related grade 3 or 4 adverse events occurred in 80% (24/30) of patients, primarily leukopenia (63.3%), lymphopenia (36.7%), anemia (26.7%), neutropenia (16.7%). The grade 1-2 potentially immune-related adverse events were chromatosis 5 (16.7%), rash 2 (6.7%), pruritus 2 (6.7%), hypothyroidism 2 (6.7%), adrenal insufficiency 2 (6.7%), No treatment-related deaths occurred.

Conclusions

Toripalimab combined with cisplatin-based concurrent IMRT was tolerable and showed promising antitumor activity in patients with LACC, while immunotherapy-related toxicities should be carefully managed.

Clinical trial identification

NCT04368273.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Shanghai Junshi Biomedicine Technology Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.